Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2484
+0.00461.89%
Post-market: 0.2420-0.0064-2.58%17:45 EDT
Volume:712.39K
Turnover:177.13K
Market Cap:11.02M
PE:-0.15
High:0.2520
Open:0.2450
Low:0.2401
Close:0.2438
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.73
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.45
PE(LYR):-0.14

Loading ...

VistaGen Files Form 3 as Director Douglas J. Williamson Reports no Beneficial Ownership

Reuters
·
Jul 31

VistaGen Names Douglas J. Williamson to Board of Directors

Reuters
·
Jul 31

Vistagen Appoints Douglas J. Williamson to Its Board of Directors

THOMSON REUTERS
·
Jul 31

Vistagen Announces Topline and Post-hoc Data from Palisade-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Reuters
·
Jul 06

Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)

TIPRANKS
·
Jul 06

VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Jul 01

Vistagen Tumbles as Social Anxiety Drug Misses Main Goal in Late-stage Trial

Reuters
·
Jun 30

Vistagen Therapeutics Says Fasedienol Didn't Meet Primary Endpoint in Study

Dow Jones
·
Jun 30

Vistagen Says Fasedienol Misses Primary Endpoint in Palisade-4 Phase 3 Social Anxiety Trial

Reuters
·
Jun 30

Vistagen Announces Topline and Post-hoc Data from Palisade-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics - Plans to Meet with FDA on Registration Pathway for Fasedienol with Future Phase 3 Trial

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics Inc: Fasedienol Did not Achieve Statistically Significant Improvement on Primary and Secondary Endpoints

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics - Post-hoc Analysis Shows Nominal Statistical Significance for Fasedienol in Very Severe Social Anxiety Subgroup

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics Inc: Favorable Safety and Tolerability Data were Consistent with Previous Clinical Trials

THOMSON REUTERS
·
Jun 30

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Jun 30

VistaGen directors FitzPatrick, Curley to step down after 2026 annual meeting

Reuters
·
Jun 18

Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth

TIPRANKS
·
Jun 17

VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

Benzinga Earnings
·
Jun 16

VistaGen FY26 net loss widens to $69.7 million; R&D expense rises to $55 million

Reuters
·
Jun 16

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jun 16